Tiger

How to Negotiate with Big Ortho Strategics Without Losing Control

Heads up Startup leaders! This could be the most important article that you will read this year. For an early-stage […]

🔴 Tiger’s Red-Hot Innovator of the Week: UK startup may eliminate hip dislocations.

There isn’t a good orthopedics solution for every patient—particularly in hips. Traditional ball-and-socket implants face persistent failure modes that remain

[Tiger’s Weekly Intel] – High-Growth Collisions: Bio Acquisition, Meduloc Raise, and ASC Workflow AI Takes Off

Observation The ortho venture space appears to be rewarding high-growth startup platforms that merge structural hardware with digital ecosystem integration.

The GLP-1s unlocking a new wave of total joint patients

When GLP-1 receptor agonists and those new multi-agonist weight-loss drugs started blowing up the headlines, the initial knee-jerk reaction across

Kickbacks still pay off in ortho—just not equally.

You can’t make this stuff up. It’s real. There is an unbalanced incentive and punishment scale when defrauding Medicare in

One Question That Exposes Fake Startup Value – The Disappearance Question.

Here’s a simple test that separates real startups from road kill: If your product disappeared tomorrow, would customers actively seek

There are always more than two options

Talented people in our industry often ask me for help with a big career decision. They’re usually trying to choose

🔴 Tiger’s Red-Hot Innovator of the Week – UK startup tackles Joint Preservation’s hardest problem: The Knee Treatment Gap

There isn’t a good orthopedics solution for every patient. Particularly in knees. There is a massive, gaping hole in treatments.

[Tiger’s Weekly Intel] – Meduloc funding, BoneSupport Reimbursement, Pediatric Expansions

This is the kind of week I like to see. No flashy billion-dollar distractions—just real companies solving real problems and

How Many Employees Do You Really Need?

One simple metric is to measure the number of W2s per $1M of revenue. So what is appropriate as an

How Startups can play and win with Strategics.

In our latest BoneChat roundtable, we I sat down with the king of strategic deals, Mike Minette. Read about Mike’s

We have entered “ortho consolidation season” driven mostly by survival.

If you’ve been tracking deal flow across orthopedics, spine, and regenerative medicine over the past few months, you’ve probably noticed

Portable > Local

If you want to predict which ortho companies will scale and which will stall out in capital committees, ignore the

The quiet $350M biologics acquisition and why it happened.

While most of the ortho world was looking the other way, MiMedx (MDXG) quietly pulled the trigger on acquiring Sanara

🔴 Tiger’s Red-Hot Innovator of the Week – Michigan startup is closing the recovery gap after TKA.

“Joint replacement is one of the most successful procedures in modern medicine… until the patient walks out of the OR.”

[Tiger’s Weekly Intel] – Key Regulatory Clearances, IP Acquisitions, and M&A Activity

As we close out July 2026, our industry demonstrated steady momentum. Rather than large-scale venture funding rounds, activity centered on

Why Single-Product Ortho Startups Get Trapped at the Local Maximum

Every orthopedic entrepreneur dreams of the endless upward slope. You build a strong first product, clear regulatory hurdles, win champion

The Death of the “Me-Too” Implant: 4 Startup Megatrends Dominating 2026

If you follow the venture flow in orthopedics, you already know the era of the “me-too” implant is dead. Pure

Sharing real-world playbooks from Ortho Founders

I try to be useful for the ortho entrepreneur. The goal of this blog posting is simple: pull back the

🔴 Tiger’s Red-Hot Innovator of the Week – San Diego spine startup has created an integrated ecosystem for ASCs

Surgical hardware and digital intelligence are converging. In particular, we are watching ortho/spine market reach an inflection point, driven by

[Tiger’s Weekly Intel] – Some Startups found progress through acquisitions, FDA clearances, capital funding, and commercial momentum.

The past week highlighted key momentum across both U.S. and international orthopedic startups, marked by big M&A acquisitions, navigation clearances,

Agency is the real prize.

Agency is the real prize. Not status. Not the title. Not the salary line that shrinks with inflation every year

How Ortho startups can break through the Hospital lockout.

Let’s face it. All the innovation in orthopedics comes from startups these days. However, your better technology and better outcomes

Founders Beware ! Funding scammers are targeting Medtech startups

This is really happening. Learn about it and beware. Let’s face it: the current capital-raising environment for early-stage orthopedic and

Financial Health: What to check before you join a new company.

This is important… and often overlooked. In orthopedics, we love to talk about clinical data, disruptive tech, and market opportunity.

The Strategy Behind the DePuy X-PAC Acquisition

DePuy Synthes announced its acquisition of Expanding Innovations (EI), officially bringing the X-PAC® expandable interbody platform under the DPY umbrella.

🔴 Tiger’s Red-Hot Innovator of the Week: UK startup brings predictive real-time protection to your knee.

This week we are shifting the Sports Med innovation discussion from passive bracing —> to predictive real-time knee protection. Historically,

[Tiger’s Weekly Intel] – M&A, Handheld Robotics, and 3D Biomimetic Implants Drive the Shift to ASC-Focused Outpatient Care

Most of the industry is reading self-serving press releases, but here is your intel for the week. The trend continues

How to torch $300M building a surgical robot company.

It is one of the most seductive pitches in modern venture capital: “We are going to disrupt Intuitive Surgical’s DaVinci.”

The Great Unbundling of Orthopedics Has Begun

For decades, the dominant orthopedic corporate strategy was portfolio consolidation—creating “one-stop-shop” conglomerates that could bundle joints, spine, trauma, and sports

The Brutal 10-Year Verdict: How Shaving the Meniscus Actually Ruins the Knee

Article Summary The orthopedic industry just got handed a 10-year bill it can’t ignore. For decades, arthroscopic partial meniscectomy was

🔴 Tiger’s Red-Hot Innovator of the Week – French startup simplifying ACJ stabilization with synthetic ligament.

I believe that we are entering the Sports Med wave with accelerating innovation in this space. Here is my scoring

[Tiger’s Weekly Intel] – VB Spine’s acquisition, Movmedix’s FDA clearance, and Miach’s clinical data.

Most of the industry is reading self-serving press releases, but here is your intel on what really happened last week.

The Reverse Total Hip — Promise, Perils, and the Data That Will Decide

We’ve all heard the drumbeat: total hip arthroplasty (THA) is a mature, commodity market. Implants are reliable, survival curves flatline

When the Race to the Bottom Lands You in the Power Tool Aisle

We often talk about implant “commoditization” in orthopedics. It’s that spooky campfire story that consultants use to scare medical sales

A quick dive into the 3 types of publicly traded Orthopedic companies.

Something different today. The orthopedic sector continues to showcase a fascinating divide of financial health. When looking at the public

Why Ortho innovation works better inside a Venture Studio

The traditional playbook for taking an idea to commercialization is broken. Historically, a surgeon has a great new product idea

Making sense of the ZB acquisition of iovera°

Tiger’s Strategic Summary ZB knows that implants are becoming commodities with an inevitable race to the bottom. ZB also knows

🔴 Tiger’s Red-Hot Innovator of the Week – Startup simplifying biceps tenodesis with sutureless anchor.

I believe that we are entering the Sports Med wave with accelerating innovation in this space. Below is my scoring of

[Tiger’s Weekly Intel] – Niche M&A, Startup Fundings, Pivots to AI Workflow and Localized Post-Surgical Pain Management.

Most of the industry is reading silly press releases, but here is your 7-day market update. Now that 2026 H1

The Tiger Dashboard – July 2026

I’m sharing this month’s DASHBOARD—the same intelligence I use to track new startups currently punching above their weight, M&A and

Insights into the venture “bottom” for ortho innovators.

It’s been a rough few years for orthopedic innovators needed capital. My short summary of the capital allocators during this

Death of the Ortho Sales Rep (or how we lost our autonomy & our surgeons).

If you’ve been in the orthopedics game long enough, you remember the Golden Era. Thirty years ago, being an ortho

Why Ortho Startups Fail the Reimbursement Reality Test

What this article will teach you. Reimbursement isn’t a math problem; it’s a structural maze. Stop building your commercial strategy

The Equity Percentage Trap

You are looking at your offer letter from an early-stage orthopedic company. You can understand the base salary, the bonus

🔴 Tiger’s Red-Hot Innovator of the Week – Startup enhancing anchor outcomes with real-time AI Intelligence during surgery.

For decades, the sports medicine market has been defined by the same frustrating tradeoffs: mechanical weaknesses in repair setups, clunky

Author name: Tiger